AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15115982 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 144
Study 15115982 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study 11893049 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma One Bond
Number of subjects: 30
Study 11893049 — intervention group
Group type: EXPERIMENTAL
Intervention: UniFil Bond
Number of subjects: 30
Study 11893049 — intervention group
Group type: EXPERIMENTAL
Intervention: Mega Bond
Number of subjects: 30
Study 11893049 — intervention group
Group type: COMPARATOR
Intervention: Vaseline coating (additional group)
Number of subjects: 30
Study 9457393 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2) therapy (8‐18 x 10(6) IU/m2 x 5 days) by continuous intravenous infusion with a 72‐hour rest period between each cycle, followed by subcutaneous maintenance rIL‐2 therapy at lower doses for 5 days/month
Number of subjects: 24
Study 9457393 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL‐2 therapy
Number of subjects: 24
Study 9457393 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 24
Study 7870534 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mph simulated pitch speed
Number of subjects: 44
Study 7870534 — intervention group
Group type: EXPERIMENTAL
Intervention: 70 mph simulated pitch speed
Number of subjects: 44
Study 3129390 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg bd)
Number of subjects: 43
Study 3129390 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin (1,000 mg tid)
Number of subjects: 43
Study 30134549 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic acid and inulin
Number of subjects: 0
Study 30134549 — intervention group
Group type: COMPARATOR
Intervention: High fat diet (HFD) untreated mice
Number of subjects: 0
Study 27004663 — intervention group
Group type: EXPERIMENTAL
Intervention: Marker placement laser device
Number of subjects: 38
Study 27004663 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot with three different tape conditions
Number of subjects: 38
Study 27004663 — intervention group
Group type: EXPERIMENTAL
Intervention: Barefoot
Number of subjects: 38
Study 25776067 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-CON therapy (Optimised concomitant therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), clarithromycin (500 mg b.d.), and metronidazole (500 mg b.d.) for 14 days
Number of subjects: 777
Study 25776067 — intervention group
Group type: COMPARATOR
Intervention: OPT-TRI therapy (Optimised triple therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), and clarithromycin (500 mg b.d.) for 14 days
Number of subjects: 777
Study 25776067 — intervention group
Group type: EXPERIMENTAL
Intervention: OPT-CON therapy
Number of subjects: 777
Study 25776067 — intervention group
Group type: COMPARATOR
Intervention: OPT-TRI therapy
Number of subjects: 777
Study 23574458 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g tranexamic acid intravenously over 10 min before elective cesarean section
Number of subjects: 740
Study 23574458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 740
Study 20105396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (SP6, KI3, KI6, BL60, LI4, and acupressure on BL67)
Number of subjects: 84
Study 20105396 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 84
Study 20105396 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 84
Study 19134445 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wrist bands
Number of subjects: 18
Study 19134445 — intervention group
Group type: COMPARATOR
Intervention: Placebo bands
Number of subjects: 18
Study 19134445 — intervention group
Group type: COMPARATOR
Intervention: Standard care treatment with no bands
Number of subjects: 18
Study 15059051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheepskin mattress overlay for the duration of hospital stay (218 patients)
Number of subjects: 441
Study 15059051 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment as determined by ward staff (223 patients)
Number of subjects: 441
Study 15059051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheepskin group
Number of subjects: 441
Study 11481298 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 6.0/0.75 g q12h
Number of subjects: 0
Study 11481298 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 8.0/1.0 g q12h
Number of subjects: 0
Study 9745797 — intervention group
Group type: EXPERIMENTAL
Intervention: Underprediction information condition
Number of subjects: 40
Study 9745797 — intervention group
Group type: COMPARATOR
Intervention: Correct information condition
Number of subjects: 40
Study 8149358 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa methyl ester (ME)
Number of subjects: 11
Study 8149358 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 11
Study 8149358 — intervention group
Group type: EXPERIMENTAL
Intervention: half the dose of ME together with a halved tablet of Sinemet CR
Number of subjects: 11
Study 2966825 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 152
Study 2966825 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 152
Study 29956199 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (active treatment), 8 sessions of 5 minutes each over 4 weeks
Number of subjects: 40
Study 29956199 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study 26984534 — intervention group
Group type: EXPERIMENTAL
Intervention: web-based Kanker Nazorg Wijzer intervention
Number of subjects: 432
Study 26984534 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior-related modules
Number of subjects: 432
Study 26984534 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual cancer aftercare)
Number of subjects: 432
Study 24785885 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakkonto Extract‐A, 6 g/day
Number of subjects: 340
Study 24785885 — intervention group
Group type: COMPARATOR
Intervention: Pabron Gold‐A, 3.6 g/day
Number of subjects: 340
Study 22269590 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid plaque ultrasonographic screening (US group)
Number of subjects: 536
Study 22269590 — intervention group
Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 536
Study 20580604 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage containing Lactobacillus casei strain Shirota (40 billion bacterial cells/bottle for 4 weeks, 1 bottle/day)
Number of subjects: 34
Study 20580604 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage containing Lactobacillus casei strain Shirota
Number of subjects: 34
Study 20580604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 17909399 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated sea-level (SL) conditions
Number of subjects: 20
Study 17909399 — intervention group
Group type: COMPARATOR
Intervention: Local normoxic hypobaria
Number of subjects: 20
Study 16228839 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous gentamycin-collagen implant
Number of subjects: 80
Study 16228839 — intervention group
Group type: COMPARATOR
Intervention: Collagen implant without antibiotics (placebo)
Number of subjects: 80
Study 11303543 — intervention group
Group type: EXPERIMENTAL
Intervention: Support by the Diabetes Service
Number of subjects: 246
Study 11303543 — intervention group
Group type: COMPARATOR
Intervention: Conventional general practice care
Number of subjects: 246
Study 9129563 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral codeine administration
Number of subjects: 10
Study 9129563 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo administration
Number of subjects: 10
Study 9129563 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters of morphine
Number of subjects: 10
Study 8035452 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative education
Number of subjects: 3077
Study 8035452 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3077
Study 3313489 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 2000
Study 30705369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline nasal irrigation and gargling (HSNIG)
Number of subjects: 68
Study 30705369 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 68
Study 26542990 — intervention group
Group type: EXPERIMENTAL
Intervention: HG-Reg (handgrip-Regadenoson)
Number of subjects: 60
Study 26010359 — intervention group
Group type: EXPERIMENTAL
Intervention: Zamzee intervention
Number of subjects: 182
Study 26010359 — intervention group
Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 182
Study 26010359 — intervention group
Group type: COMPARATOR
Intervention: Active control group (commercially available active videogame)
Number of subjects: 182
Study 23585559 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg for 6 weeks, 10 mg for 1 week, 5 mg for 1 week)
Number of subjects: 160
Study 23585559 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 21643711 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial working memory task
Number of subjects: 745
Study 21643711 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory task
Number of subjects: 745
Study 21643711 — intervention group
Group type: COMPARATOR
Intervention: Matched no‐memory control tasks
Number of subjects: 745
Study 19139319 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU per CPR cycle) plus epinephrine (1 mg per CPR cycle)
Number of subjects: 100
Study 19139319 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress-dose hydrocortisone sodium succinate (300 mg daily for 7 days maximum)
Number of subjects: 100
Study 19139319 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution placebo plus epinephrine (1 mg per CPR cycle)
Number of subjects: 100
Study 19139319 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study 16738026 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical self-definition
Number of subjects: 0
Study 16738026 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 0
Study 16738026 — intervention group
Group type: COMPARATOR
Intervention: Global self-views
Number of subjects: 0
Study 15475020 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based nutrition intervention in Alabama
Number of subjects: 2106
Study 15475020 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based nutrition intervention in Minnesota
Number of subjects: 2106
Study 11774703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild walking exercise (30 minutes a day)
Number of subjects: 52
Study 11774703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no walking exercise)
Number of subjects: 52
Study 11774703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild walking exercise
Number of subjects: 52
Study 9203725 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (OPV) administered in the rainy season
Number of subjects: 46
Study 9203725 — intervention group
Group type: COMPARATOR
Intervention: Trivalent oral poliovirus vaccine (OPV) administered in other seasons
Number of subjects: 46
Study 8278816 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (auranofin and methotrexate)
Number of subjects: 0
Study 8278816 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0
Study 8278816 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0
Study 30561227 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP11B2 (‐344T) allele in hypertensive patients
Number of subjects: 100
Study 30561227 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP11B2 ‐344TT genotype
Number of subjects: 100
Study 29967525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 intake during infancy
Number of subjects: 331
Study 29967525 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 status in infancy
Number of subjects: 331
Study 29967525 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 status
Number of subjects: 331
Study 27095529 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PAPP (PAPP >0.50)
Number of subjects: 175
Study 27095529 — intervention group
Group type: COMPARATOR
Intervention: Nonoptimal PAPP (PAPP ≤0.50)
Number of subjects: 175
Study 27095529 — intervention group
Group type: EXPERIMENTAL
Intervention: PAPP as a continuous variable
Number of subjects: 175
Study 27095529 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model with pulmonary capillary wedge pressure, creatinine, and nonoptimal PAPP
Number of subjects: 175
Study 24726174 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (500 mg)
Number of subjects: 200
Study 24726174 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint irrigation with TXA (3 g in 100 cc saline)
Number of subjects: 200
Study 24726174 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA injection through the drain (1.5 g)
Number of subjects: 200
Study 24726174 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 200
Study 21422238 — intervention group
Group type: EXPERIMENTAL
Intervention: AR9281 (250 mg)
Number of subjects: 0
Study 21422238 — intervention group
Group type: EXPERIMENTAL
Intervention: AR9281 (500 mg)
Number of subjects: 0
Study 21422238 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of AR9281 (100-400 mg every 8 hours)
Number of subjects: 0
Study 21422238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19904559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0
Study 19904559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab group
Number of subjects: 0
Study 19904559 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18242008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch and nicotine gum
Number of subjects: 103
Study 18242008 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 103
Study 16183617 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-item Rey memory test combined with WAIS-III Digit Span test
Number of subjects: 96
Study 16183617 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-item Rey memory test combined with WAIS-III Digit Span test
Number of subjects: 96
Study 16183617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of total score from the 16-item test with digits forward span
Number of subjects: 96
Study 16183617 — intervention group
Group type: COMPARATOR
Intervention: Any single test score or any other combination of digit span score with a Rey score
Number of subjects: 96
Study 12544991 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (500 mg)
Number of subjects: 36
Study 10551192 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice Assessment Report (PAR)
Number of subjects: 56
Study 10551192 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing Medical Education Plan (CMEP)
Number of subjects: 56
Study 10551192 — intervention group
Group type: COMPARATOR
Intervention: Control group (PAR only)
Number of subjects: 56
Study 8694158 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen
Number of subjects: 24
Study 8694158 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide in oxygen
Number of subjects: 24
Study 1997806 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct feedback (greater left hemisphere low frequency activity)
Number of subjects: 24
Study 1997806 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect feedback (greater right hemisphere low frequency activity)
Number of subjects: 24
Study 1997806 — intervention group
Group type: COMPARATOR
Intervention: No feedback control
Number of subjects: 24
Study 6217886 — intervention group
Group type: EXPERIMENTAL
Intervention: MOF plus streptozotocin (MOF-Strep)
Number of subjects: 75
Study 6217886 — intervention group
Group type: COMPARATOR
Intervention: MOF
Number of subjects: 75
Study 6217886 — intervention group
Group type: EXPERIMENTAL
Intervention: MOF-Strep
Number of subjects: 75
Study 30068817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C was above predefined limits)
Number of subjects: 216
Study 30068817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 29903578 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable brace
Number of subjects: 44
Study 29903578 — intervention group
Group type: COMPARATOR
Intervention: Cast
Number of subjects: 44
Study 26843796 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect and self-affirmation intervention with motivational interviewing
Number of subjects: 238
Study 26843796 — intervention group
Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 238
Study 24484726 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily
Number of subjects: 150
Study 24484726 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 23111049 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Feedback (PF)
Number of subjects: 25
Study 23111049 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Feedback (NF)
Number of subjects: 25
Study 19606092 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal melatonin (MEL) delivery during daytime
Number of subjects: 0
Study 19606092 — intervention group
Group type: COMPARATOR
Intervention: Oral melatonin (MEL)
Number of subjects: 0
Study 17697058 — intervention group
Group type: EXPERIMENTAL
Intervention: IDF criteria
Number of subjects: 3042
Study 17697058 — intervention group
Group type: COMPARATOR
Intervention: NCEP criteria
Number of subjects: 3042
Study 15353873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg daily)
Number of subjects: 42
Study 15353873 — intervention group
Group type: EXPERIMENTAL
Intervention: Eprosartan (400-800 mg daily)
Number of subjects: 42
Study 15353873 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose eprosartan or enalapril
Number of subjects: 42
Study 11593101 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan (150-300 mg once daily)
Number of subjects: 34
Study 11593101 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 34
Study 11593101 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo run-in period)
Number of subjects: 34
Study 9724827 — intervention group
Group type: COMPARATOR
Intervention: EN-9527 (standard medical nutritional)
Number of subjects: 79
Study 9724827 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-9528 (renal nutritional)
Number of subjects: 79
Study 9724827 — intervention group
Group type: EXPERIMENTAL
Intervention: EN-9529 (renal nutritional with fructooligosaccharides)
Number of subjects: 79
Study 7988779 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitostanol ester (3 g daily)
Number of subjects: 11
Study 2594908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital (30 mg per dose)
Number of subjects: 12
Study 2594908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2594908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 12
Study 31325604 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 342
Study 31325604 — intervention group
Group type: COMPARATOR
Intervention: Non-Chinese herbal medicine (non-CHM)
Number of subjects: 342
Study 29037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI < 25 kg/m2
Number of subjects: 327
Study 29037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal BMI > 30 kg/m2
Number of subjects: 327
Study 29037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers giving birth to infants with macrosomia
Number of subjects: 327
Study 29037224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers giving birth to infants classified as large-for-gestational-age (LGA)
Number of subjects: 327
Study 25634811 — intervention group
Group type: EXPERIMENTAL
Intervention: BOOCS program participants (1,565 males and 742 females)
Number of subjects: 21626
Study 25634811 — intervention group
Group type: COMPARATOR
Intervention: Nonparticipant comparative obese controls (1,230 males and 605 females)
Number of subjects: 21626
Study 24144896 — intervention group
Group type: COMPARATOR
Intervention: GSK1265744 (5 mg)
Number of subjects: 59
Study 24144896 — intervention group
Group type: COMPARATOR
Intervention: GSK1265744 (30 mg)
Number of subjects: 59
Study 24144896 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 59
Study 21762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Provided ED process information (n = 336)
Number of subjects: 1011
Study 21762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Provided ED process information plus predicted service delivery times (n = 333)
Number of subjects: 1011
Study 21762230 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 342)
Number of subjects: 1011
Study 21762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Waiting room time (every 10-minute increase)
Number of subjects: 1011
Study 21762230 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 35 years and older
Number of subjects: 1011
Study 19430944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow CON contractions (5-1)
Number of subjects: 9
Study 19430944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow ECC contractions (1-5)
Number of subjects: 9
Study 19430944 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow CON and ECC contractions (3-3)
Number of subjects: 9
Study 19430944 — intervention group
Group type: COMPARATOR
Intervention: High-intensity exercise at normal velocity (1-1)
Number of subjects: 9